Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer

M. Bertrand; P. Multhauf; C. Presant; D. Rappaport; D. W. Blayney; B. I. Carr; G. Cecchi; J. H. Doroshow; E. Emont; D. Goldberg

Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer

M. Bertrand, P. Multhauf, C. Presant, D. Rappaport, D. W. Blayney, B. I. Carr, G. Cecchi, J. H. Doroshow, E. Emont, D. Goldberg

Ente Ospedaliero Specializzato in Gastroenterologia "Saverio de Bellis"

Research output: Contribution to journal › Article

Abstract

Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m² iv) on Day 1, cisplatin (40 mg/m² iv) on Days 1-3 and etoposide (100 mg/m² iv) on Days 1-3 (or 80 mg/m² iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European Organization for Research on Treatment of Cancer that this type of triple combination chemotherapy is not recommended for the treatment of NSCLC.

Original language	English
Pages (from-to)	1335-1336
Number of pages	2
Journal	Cancer Treatment Reports
Volume	69
Issue number	11
Publication status	Published - 1985

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

Fingerprint Dive into the research topics of 'Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this

Bertrand, M., Multhauf, P., Presant, C., Rappaport, D., Blayney, D. W., Carr, B. I., Cecchi, G., Doroshow, J. H., Emont, E., & Goldberg, D. (1985). Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer. Cancer Treatment Reports, 69(11), 1335-1336.

@article{3f0d7e447eb34d02b592b87a70fa4b38,

title = "Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer",

abstract = "Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m2 iv) on Day 1, cisplatin (40 mg/m2 iv) on Days 1-3 and etoposide (100 mg/m2 iv) on Days 1-3 (or 80 mg/m2 iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European Organization for Research on Treatment of Cancer that this type of triple combination chemotherapy is not recommended for the treatment of NSCLC.",

author = "M. Bertrand and P. Multhauf and C. Presant and D. Rappaport and Blayney, {D. W.} and Carr, {B. I.} and G. Cecchi and Doroshow, {J. H.} and E. Emont and D. Goldberg",

year = "1985",

language = "English",

volume = "69",

pages = "1335--1336",

journal = "Cancer Treatment Reports",

issn = "0361-5960",

publisher = "U.S. National Cancer Institute",

number = "11",

}

TY - JOUR

T1 - Phase II trial of etoposide, vincristine, and high-dose cisplatin in advanced non-small cell lung cancer

AU - Bertrand, M.

AU - Multhauf, P.

AU - Presant, C.

AU - Rappaport, D.

AU - Blayney, D. W.

AU - Carr, B. I.

AU - Cecchi, G.

AU - Doroshow, J. H.

AU - Emont, E.

AU - Goldberg, D.

PY - 1985

Y1 - 1985

N2 - Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m2 iv) on Day 1, cisplatin (40 mg/m2 iv) on Days 1-3 and etoposide (100 mg/m2 iv) on Days 1-3 (or 80 mg/m2 iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European Organization for Research on Treatment of Cancer that this type of triple combination chemotherapy is not recommended for the treatment of NSCLC.

AB - Twenty-two patients with advanced non-small cell lung cancer (NSCLC), previously unexposed to chemotherapy, were treated with a combination of vincristine (1.4 mg/m2 iv) on Day 1, cisplatin (40 mg/m2 iv) on Days 1-3 and etoposide (100 mg/m2 iv) on Days 1-3 (or 80 mg/m2 iv on Days 1-3 for patients previously treated with radiation. This trial supports the conclusion of the European Organization for Research on Treatment of Cancer that this type of triple combination chemotherapy is not recommended for the treatment of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0022353082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022353082&partnerID=8YFLogxK

M3 - Article

C2 - 4092199

AN - SCOPUS:0022353082

VL - 69

SP - 1335

EP - 1336

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 11

ER -